Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

297
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
297
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

3.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K
Open and closed-loop control systems01:17

Open and closed-loop control systems

1.1K
Control systems are foundational elements in automation and engineering. They are broadly categorized into open-loop and closed-loop systems. These classifications hinge on the presence or absence of feedback mechanisms, significantly influencing the system's performance, complexity, and application.
An open-loop control system operates without feedback from the output. It consists of two primary elements: the controller and the controlled process. The controller receives an input signal...
1.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

291
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
291
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

1.5K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

1.5K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

First Use of Control-IQ+ Technology in Newly Indicated Populations.

Diabetes technology & therapeutics·2026
Same author

Editorial: Diabetes and pregnancy: optimizing maternal and fetal outcomes through advanced technologies.

Frontiers in endocrinology·2026
Same author

A hierarchical network model for the estimate of the energy expenditure in individuals with type 1 diabetes.

Engineering applications of artificial intelligence·2026
Same author

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Diabetes, obesity & metabolism·2026
Same author

Maternal Hyperglycemia and Adult Offspring Overweight and Obesity: Is Birthweight a Mediator?

American journal of perinatology·2026

Related Experiment Video

Updated: Oct 2, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K

Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm.

Basak Ozaslan1,2, Carol J Levy3, Yogish C Kudva4

  • 1Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Boston, Massachusetts, USA.

Diabetes Technology & Therapeutics
|March 1, 2022
PubMed
Summary

This study shows that a pregnancy-specific zone model predictive control (zone-MPC) algorithm for closed-loop insulin delivery is feasible for pregnant women with type 1 diabetes. The system improved glucose control, reducing time spent with high or low blood sugar levels.

Keywords:
Artificial pancreasClosed loop controlGlucose controlOutpatientPregnancyType 1 diabetes

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications
09:08

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

12.6K

Related Experiment Videos

Last Updated: Oct 2, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.8K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications
09:08

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

12.6K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Artificial Pancreas Technology

Background:

  • Type 1 diabetes (T1D) in pregnancy requires careful glucose management to ensure maternal and fetal well-being.
  • Traditional insulin therapy and continuous glucose monitoring (CGM) augmented pump therapy present challenges in achieving optimal glycemic control during pregnancy.
  • Closed-loop control (CLC) systems offer a potential solution for improved glucose management in pregnant individuals with T1D.

Purpose of the Study:

  • To evaluate the feasibility and effectiveness of a pregnancy-specific zone model predictive control (zone-MPC) algorithm for closed-loop insulin delivery.
  • To assess glucose control metrics, including time in range, and postprandial glucose levels in pregnant women with T1D using the zone-MPC system.
  • To compare glucose control during CLC with a baseline run-in period in a supervised outpatient setting.

Main Methods:

  • A multicenter, supervised outpatient study involving pregnant women with T1D (14-32 weeks gestation) using CGM-augmented pump therapy.
  • Evaluation of a pregnancy-specific zone-MPC algorithm integrated with the interoperable artificial pancreas system (iAPS) on a smartphone.
  • Comparison of CGM data over a 2-day CLC period against a 1-week run-in period, with unrestricted meals and activities.

Main Results:

  • The CLC system significantly increased the percentage of time in the target glucose range (63-140 mg/dL) compared to the run-in period (81.5% vs. 64%, P=0.007).
  • CLC resulted in significantly less time with glucose levels above 140 mg/dL (16.5% vs. 30.8%, P=0.029) and below 63 mg/dL (2.0% vs. 5.2%, P=0.039).
  • Overnight glucose control showed reduced time above 250 mg/dL (0% vs. 3.9%, P=0.030) and a lower glucose standard deviation (23.8 mg/dL vs. 42.8 mg/dL, P=0.007) during CLC.

Conclusions:

  • The pregnancy-specific zone-MPC algorithm is feasible for closed-loop insulin delivery in pregnant women with T1D.
  • The system demonstrated improved glycemic control, including reduced hyperglycemia and hypoglycemia, compared to standard therapy.
  • These findings contribute to the limited data on CLC system use during pregnancy, supporting further research in this area.